Effects of Therapy with [177Lu-DOTA0, Tyr3]Octreotate in Patients with Paraganglioma, Meningioma, Small Cell Lung Carcinoma, and Melanoma

Therapy using the radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate (177Lu-octreotate) (DOTA is 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid) has been used primarily in gastroenteropancreatic neuroendocrine tumors. Here we present the effect...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The Journal of nuclear medicine (1978) 2006-10, Vol.47 (10), p.1599-1606
Hauptverfasser:	van Essen, Martijn, Krenning, Eric P, Kooij, Peter P, Bakker, Willem H, Feelders, Richard A, de Herder, Wouter W, Wolbers, John G, Kwekkeboom, Dik J
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Amino acids Carcinoma, Small Cell - radiotherapy Carcinoma, Small Cell - secondary Cells Clinical outcomes Eye Neoplasms - pathology Eye Neoplasms - radiotherapy Female Hospitals Humans Kidneys Lung cancer Lung Neoplasms - pathology Lung Neoplasms - radiotherapy Lutetium Male Melanoma - radiotherapy Melanoma - secondary Meningeal Neoplasms - pathology Meningeal Neoplasms - radiotherapy Meningioma - radiotherapy Meningioma - secondary Middle Aged Neoplasm Metastasis Nuclear medicine Octreotide - analogs & derivatives Octreotide - therapeutic use Paraganglioma - radiotherapy Paraganglioma - secondary Patients Radioisotopes Radiopharmaceuticals - therapeutic use Studies Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!